347 related articles for article (PubMed ID: 31941438)
21. Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study.
McCracken JT; McGough JJ; Loo SK; Levitt J; Del'Homme M; Cowen J; Sturm A; Whelan F; Hellemann G; Sugar C; Bilder RM
J Am Acad Child Adolesc Psychiatry; 2016 Aug; 55(8):657-666.e1. PubMed ID: 27453079
[TBL] [Abstract][Full Text] [Related]
22. Guanfacine Use in Children With Down Syndrome and Comorbid Attention-Deficit Hyperactivity Disorder (ADHD) With Disruptive Behaviors.
Capone GT; Brecher L; Bay M
J Child Neurol; 2016 Jul; 31(8):957-64. PubMed ID: 26936058
[TBL] [Abstract][Full Text] [Related]
23. Differential effects of ADHD medications on impulsive action in the mouse 5-choice serial reaction time task.
Fitzpatrick CM; Andreasen JT
Eur J Pharmacol; 2019 Mar; 847():123-129. PubMed ID: 30690006
[TBL] [Abstract][Full Text] [Related]
24. Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder.
Bukstein OG; Head J
Expert Opin Pharmacother; 2012 Oct; 13(15):2207-13. PubMed ID: 22957772
[TBL] [Abstract][Full Text] [Related]
25. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
Newcorn JH; Stein MA; Childress AC; Youcha S; White C; Enright G; Rubin J
J Am Acad Child Adolesc Psychiatry; 2013 Sep; 52(9):921-30. PubMed ID: 23972694
[TBL] [Abstract][Full Text] [Related]
26. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Childress AC
Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
[TBL] [Abstract][Full Text] [Related]
27. ▼Guanfacine for ADHD in children and adolescents.
Drug Ther Bull; 2016 May; 54(5):56-60. PubMed ID: 27173784
[TBL] [Abstract][Full Text] [Related]
28. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy.
Hirota T; Schwartz S; Correll CU
J Am Acad Child Adolesc Psychiatry; 2014 Feb; 53(2):153-73. PubMed ID: 24472251
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
Iwanami A; Saito K; Fujiwara M; Okutsu D; Ichikawa H
J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32297719
[TBL] [Abstract][Full Text] [Related]
30. Neural mechanisms underlying the therapeutic actions of guanfacine treatment in youth with ADHD: a pilot fMRI study.
Bédard AC; Schulz KP; Krone B; Pedraza J; Duhoux S; Halperin JM; Newcorn JH
Psychiatry Res; 2015 Mar; 231(3):353-6. PubMed ID: 25659477
[TBL] [Abstract][Full Text] [Related]
31. Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD.
Huss M; Dirks B; Gu J; Robertson B; Newcorn JH; Ramos-Quiroga JA
Eur Child Adolesc Psychiatry; 2018 Oct; 27(10):1283-1294. PubMed ID: 29442229
[TBL] [Abstract][Full Text] [Related]
32. Chronic Administrations of Guanfacine on Mesocortical Catecholaminergic and Thalamocortical Glutamatergic Transmissions.
Fukuyama K; Nakano T; Shiroyama T; Okada M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923533
[TBL] [Abstract][Full Text] [Related]
33. A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders.
Sallee F; Connor DF; Newcorn JH
J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):308-19. PubMed ID: 23782125
[TBL] [Abstract][Full Text] [Related]
34. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
Kollins SH; López FA; Vince BD; Turnbow JM; Farrand K; Lyne A; Wigal SB; Roth T
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):111-20. PubMed ID: 21476931
[TBL] [Abstract][Full Text] [Related]
35. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study.
Newcorn JH; Harpin V; Huss M; Lyne A; Sikirica V; Johnson M; Ramos-Quiroga JA; van Stralen J; Dutray B; Sreckovic S; Bloomfield R; Robertson B
J Child Psychol Psychiatry; 2016 Jun; 57(6):717-28. PubMed ID: 26871297
[TBL] [Abstract][Full Text] [Related]
36. Guanfacine extended-release (intuniv) for ADHD.
Med Lett Drugs Ther; 2010 Oct; 52(1349):82-3. PubMed ID: 21045757
[No Abstract] [Full Text] [Related]
37. Treating ADHD in Prison: Focus on Alpha-2 Agonists (Clonidine and Guanfacine).
Mattes JA
J Am Acad Psychiatry Law; 2016 Jun; 44(2):151-7. PubMed ID: 27236168
[TBL] [Abstract][Full Text] [Related]
38. Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Huss M; McBurnett K; Cutler AJ; Hervás A; Bliss C; Gao J; Dirks B; Newcorn JH
Eur Neuropsychopharmacol; 2019 Mar; 29(3):432-443. PubMed ID: 30064718
[TBL] [Abstract][Full Text] [Related]
39. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Cutler AJ; Brams M; Bukstein O; Mattingly G; McBurnett K; White C; Rubin J
J Am Acad Child Adolesc Psychiatry; 2014 Oct; 53(10):1092-101. PubMed ID: 25245353
[TBL] [Abstract][Full Text] [Related]
40. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
Faraone SV; McBurnett K; Sallee FR; Steeber J; López FA
Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
